Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Enzymatic Assay and Characterization of cyt bc1 & bd inhibitors report (opens in new window)

The Enzymatic Assay and Characterization of cyt bc1 & bd inhibitors report will describe the assay, conditions and characterisation methodology of the enzymatic assay for testing cytochrome bc1 and cytochrome bd inhibitors.

In vitro activity report for new anti-bacterial compounds (opens in new window)

The In vitro activity report for new anti-bacterial compounds will summarize the results of in vitro activity of newly identified compounds within the project against intracellular (MDR)-Mtb strains in human cells.

Purified Mtb cytochrome report (opens in new window)

The Purified Mtb cytochrome report will describe the methodology and confirmation of the purified cytochrome bc1, bc1:aa3, and bd

Continuous enzymatic assay and screening report (opens in new window)

The continuous enzymatic assay and screening report will describe the assay, conditions and characterisation methodology of the continuous enzymatic assay for testing Mtr inhibitors and the application in the High Throughput Screening campaign.

Decision on final compound FiH (opens in new window)

Short summary and scientific explanation on the final decision of the compound that will be used in the FiH. Minutes of the steering committee meeting where this will be decided are included.

In vitro synergy report for current and new anti-bacterial compounds (opens in new window)

The in vitro synergy report for current and new anti-bacterial compounds will summarize the results of in vitro synergy between antibiotics currently used in standard TB treatment regimens and newly identified anti-bacterial compounds against intracellular (MDR)-Mtb strains in human cells.

Structures of cytochrome report (opens in new window)

The Structure of cytochrome report will describe the structures revealed by Structural Biology of cytochrome bc1 and/or bc1:aa3 or bd.

HDT Target Identification and mode of action report (opens in new window)

The HDT Target Identification and mode of action report will describe the process, the methodology and summarize the identified of targets and mode of actions of lead Host Directed Therapeutics compounds.

In vitro activity of single HDT compounds report (opens in new window)

In vitro activity of single HDT compounds report will summarize the results of in vitro activity of single Host Directed Therapeutics compounds against intracellular MDRMtb strains in human cells

Website RespiriTB online (opens in new window)

The website developed for communication of all RespiriTB activities will be active and online.

Publications

Host and bacterial lipid metabolism during tuberculosis infections: possibilities to synergise host- and bacteria-directed therapies (opens in new window)

Author(s): Teun van der Klugt, Robin H. G. A. van den Biggelaar, Anno Saris
Published in: Critical Reviews in Microbiology, Issue 51, 2025, Page(s) 463-483, ISSN 1040-841X
Publisher: Taylor & Francis
DOI: 10.1080/1040841x.2024.2370979

Structural and mechanistic study of a novel inhibitor analogue of M. tuberculosis cytochrome bc1:aa3 (opens in new window)

Author(s): Amit K. Verma, Robbert Q. Kim, Dirk A. Lamprecht, Clara Aguilar-Pérez, Sarah Wong, Nicolas Veziris, Alexandra Aubry, José M. Bartolomé-Nebreda, Rodrigo J. Carbajo, Jennefer Wetzel, Meindert H. Lamers
Published in: npj Drug Discovery, Issue 2, 2025, ISSN 3005-1452
Publisher: Springer Science and Business Media LLC
DOI: 10.1038/s44386-025-00008-3

A high-throughput target-based screening approach for the identification and assessment of <i>Mycobacterium tuberculosis</i> mycothione reductase inhibitors (opens in new window)

Author(s): Natalia Smiejkowska, Lauren Oorts, Kevin Van Calster, Linda De Vooght, Rob Geens, Henri-Philippe Mattelaer, Koen Augustyns, Sergei V. Strelkov, Dirk Lamprecht, Koen Temmerman, Yann G.-J. Sterckx, Davie Cappoen, Paul Cos
Published in: Microbiology Spectrum, Issue 12, 2024, ISSN 2165-0497
Publisher: American Society for Microbiology
DOI: 10.1128/spectrum.03723-23

Host‐directed therapy to combat mycobacterial infections* (opens in new window)

Author(s): Gül Kilinç, Anno Saris, Tom H. M. Ottenhoff, Mariëlle C. Haks
Published in: Immunological Reviews, Issue 301/1, 2021, Page(s) 62-83, ISSN 0105-2896
Publisher: Blackwell Publishing Inc.
DOI: 10.1111/imr.12951

Searching for OpenAIRE data...

There was an error trying to search data from OpenAIRE

No results available

My booklet 0 0